Strides Shasun gets USFDA nod for anti-HIV drug Abacavir

The product will be manufactured at Strides Shasun’s USFDA approved facility at Bengaluru


Shares of Strides rose 1.31% to close at Rs1,056.70 on BSE, while the benchmark Sensex declined 0.19% to 27,876.61 points.
Shares of Strides rose 1.31% to close at Rs1,056.70 on BSE, while the benchmark Sensex declined 0.19% to 27,876.61 points.

Hyderabad: Strides Shasun Ltd on Tuesday said it got approval from US Food and Drug Administration (USFDA) for anti-retroviral Abacavir tablets used in the treatment of patients with HIV infection.

Strides said the US approval is for 300 mg dosage form.

The product will be manufactured at the company’s USFDA approved facility at Bengaluru and marketed by Strides in the US market, the company said in a statement.

“The product will be launched immediately,” it added.

According to IMS sales data, the US market for Abacavir is approximately $30 million.

Shares of Strides rose 1.31% to close at Rs1,056.70 on BSE, while the benchmark Sensex declined 0.19% to 27,876.61 points.

More From Livemint